Wells Fargo & Company Applied Genetic Technologies Corp Transaction History

Wells Fargo & Company

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.29 - $0.89 $52,382 - $160,760	180,630 Added 236.26%	257,083 $70,000
Q2 2022 Aug 12, 2022	SELL	$0.62 - $1.1 $4,946 - $8,775	-7,978 Reduced 9.45%	76,453 $59,000
Q1 2022 May 16, 2022	BUY	$1.07 - $2.71 $6,011 - $15,224	5,618 Added 7.13%	84,431 $90,000
Q4 2021 Feb 14, 2022	BUY	$1.87 - $2.91 $24,044 - $37,416	12,858 Added 19.5%	78,813 $149,000
Q3 2021 Nov 15, 2021	BUY	$3.01 - $4.12 $4,144 - $5,673	1,377 Added 2.13%	65,955 $199,000
Q2 2021 Aug 16, 2021	SELL	$3.62 - $5.23 $1.06 Million - $1.54 Million	-293,638 Reduced 81.97%	64,578 $252,000
Q1 2021 May 13, 2021	BUY	$3.94 - $8.19 $641,341 - $1.33 Million	162,777 Added 83.29%	358,216 $1.82 Million
Q4 2020 Feb 09, 2021	BUY	$3.99 - $5.7 $42,677 - $60,967	10,696 Added 5.79%	195,439 $799,000
Q3 2020 Nov 05, 2020	SELL	$4.38 - $6.43 $25,925 - $38,059	-5,919 Reduced 3.1%	184,743 $897,000
Q2 2020 Aug 13, 2020	BUY	$3.0 - $6.9 $204,645 - $470,683	68,215 Added 55.71%	190,662 $1.06 Million
Q1 2020 May 14, 2020	BUY	$2.36 - $9.86 $288,974 - $1.21 Million	122,447 New	122,447 $401,000

Ticker AGTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,632,200
Description
Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Pha...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.